Clinical Trial Update: An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) [Phase 3]

View source ↗

Summary

This is a Phase 3 extension study of subcutaneous secukinumab in children with Juvenile Psoriatic Arthritis and Enthesitis-related Arthritis, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enthesitis-related Arthritis
• Juvenile Psoriatic Arthritis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2025-05-23